Mankind Pharma Limited — M&A Activity 2026

Jun 2, 2026

M

Mankind

Serving Life

June 2, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 543904

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Acquisition

Pursuant to Regulation 30 read with Part A of Schedule III of the Listing Regulations, we wish to inform you that the Mankind Lifesciences Private Limited (“MLS”), a wholly owned subsidiary (“WOS”) of Mankind Pharma Limited (“Company”) which was holding 90% stake in Upakarma Ayurveda Private Limited (“Upakarma”), has acquired the remaining 10% stake of Upakarma from Kaushcorp Media LLP through a Share Purchase Agreement (“SPA”) dated June 2, 2026.

Consequent to this acquisition, Upakarma has become a WOS of MLS and a step-down WOS of the Company.

The detailed disclosures as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 for aforesaid acquisition are enclosed as Annexure-I.

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited
HITESH
KUMAR JAIN
Digitally signed by
HITESH KUMAR JAIN
Date: 2026.06.02
17:16:55 +05'30'

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600

CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

---

M

Mankind

Serving Life

Annexure-I

Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Details of event that needs to be provided	Details of Upakarma
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name: Upakarma Ayurveda Private Limited Authorized share capital: ₹2.00 Crores Paid-up share capital: ₹1.80 Crores Turnover (as on March 31, 2026): ₹ 18.02 Crores
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	This acquisition is considered as a Related Party Transaction and is carried out at arm’s length basis. The promoters or promoter group of the Company have no interest in the said acquisition. MLS has acquired the remaining 10% stake of Upakarma from Kaushcorp Media LLP through a SPA dated June 2, 2026. Accordingly, Upakarma has become a WOS of MLS and consequently, a step-down WOS of the Company.
3.	Industry to which the entity being acquired belongs;	Ayurvedic, herbal and nutraceutical products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	This acquisition will enable the Company to achieve better operational efficiencies through streamlined processes.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	June 2, 2026
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash Consideration
8.	Cost of acquisition and/or the price at which the shares are acquired;	₹75 Lakhs for acquisition of remaining 10% stake of Upakarma (payable in two tranches as per SPA)
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	After this acquisition, MLS is holding 100% stake of Upakarma
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Upakarma, incorporated on November 28, 2017, is engaged in the business of trading/selling of ayurvedic, herbal and nutraceutical products. Upakarma became step-down subsidiary of the Company on November 9, 2022. Country in which the acquired entity has presence: India Turnover of the Upakarma: ₹ in Crores
		2025-26	2024-25 2023-24
		18.02	13.06 23.04

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600

CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com